Trial Profile
An Open-Label, Phase II, Study to Evaluate Biomarkers Associated with Response to Subsequent Therapies in Subjects with HER2-Positive Metastatic Breast Cancer Receiving Treatment with Trastuzumab in Combination with Lapatinib or Chemotherapy (EGF117165)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- Acronyms DB in 3L MBC
- Sponsors GlaxoSmithKline; GSK; Novartis Pharmaceuticals
- 20 Aug 2021 Status changed from completed to discontinued.
- 13 May 2020 Status changed from active, no longer recruiting to completed.
- 18 Mar 2020 Planned End Date changed from 4 Mar 2020 to 30 Apr 2020.